Ocuphire Pharma, Inc. announced that it has entered into common stock purchase agreement with new investor Lincoln Park Capital Fund, LLC, a fund managed by Lincoln Park Capital, LLC to issue common shares for the gross proceeds of $50,000,000 on August 10, 2023. Upon the execution of the Purchase Agreement, the Company issued 246,792 shares of common stock to Lincoln Park and paid Lincoln Park $40,000, which together represents the fee for Lincoln Park?s commitment to purchase shares of the Company?s common stock under the Purchase Agreement. The investor can purchase up to $50,000,000 common shares over a 30-month period at prices per share as computed under the Purchase Agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.685 USD | -2.88% | -2.03% | -44.02% |
05-10 | Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.02% | 43.15M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- OCUP Stock
- News Ocuphire Pharma, Inc.
- Ocuphire Pharma, Inc. announced that it expects to receive $50 million in funding from Lincoln Park Capital, LLC